Ken Griffin
CYTH

Ken Griffin’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History

Ken Griffin’s Portfolio CYTH Stock Details CYTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-24,670
Closed -$31.3K – 15496
2024
Q2 		$31.3K Buy
+24,670
New +$32.6K ﹤0.01% 12226
2024
Q1 		– Sell
-54,018
Closed -$85.9K – 15619
2023
Q4 		$85.9K Buy
54,018
+39,881
+282% +$50.8K ﹤0.01% 11125
2023
Q3 		$20.1K Sell
14,137
-2,842
-17% -$4.37K ﹤0.01% 12627
2023
Q2 		$27K Sell
16,979
-1,522
-8% -$1.94K ﹤0.01% 12461
2023
Q1 		$15.6K Buy
+18,501
New +$26.3K ﹤0.01% 13248

Other funds holding CYTH

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FFVM
Founders Fund VI Management San Francisco, California $45.8K AUM 58.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Ken Griffin's CYTH Position: Q3 2024 in Review

Ken Griffin sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q3 2024, closing a stake of 24,670 shares — an estimated $31.3K sold.

Ken Griffin first reported a position in CYTH in Q1 2023 and held it in 5 quarters. The position peaked at $85.9K in Q4 2023. 19 funds tracked by Wall St. Rank hold CYTH as of Q3 2024.

  • Ken Griffin reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Ken Griffin sold 24,670 Cyclo Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $31.3K.
  • Ken Griffin first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q1 2023 and held it in 5 quarters.
  • Ken Griffin's Cyclo Therapeutics, Inc. Common Stock position peaked at $85.9K in Q4 2023.
  • 19 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.